Jing Jia, Rui Li, Junyuan Sun, Jinfeng Yang, Zhihao Hong, Weiguo Lu, Zhenyu Jia
Schools of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou, Zhejiang Province, China.
Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
Front Pharmacol. 2023 Apr 5;14:1122008. doi: 10.3389/fphar.2023.1122008. eCollection 2023.
S-phase kinase-associated protein 2 (Skp2) is a substrate-specific adaptor in Skp1-CUL1-ROC1-F-box E3 ubiquitin ligases and widely regarded as an oncogene. Therefore, Skp2 has remained as an active anticancer research topic since its discovery. Accordingly, the structure of Skp2 has been solved and numerous Skp2 inhibiting compounds have been identified. In this review, we would describe the structural features of Skp2, introduce the ubiquitination function of SCF, and summarize the diverse natural and synthetic Skp2 inhibiting compounds reported to date. The IC data of the Skp2 inhibitors or inhibiting compounds in various kinds of tumors at cellular levels implied that the cancer type, stage and pathological mechanisms should be taken into consideration when selecting Skp2-inhibiting compound for cancer treatment.
S期激酶相关蛋白2(Skp2)是Skp1-CUL1-ROC1-F盒E3泛素连接酶中的一种底物特异性衔接子,被广泛认为是一种癌基因。因此,自发现以来,Skp2一直是一个活跃的抗癌研究课题。相应地,Skp2的结构已被解析,并且已经鉴定出许多Skp2抑制化合物。在这篇综述中,我们将描述Skp2的结构特征,介绍SCF的泛素化功能,并总结迄今为止报道的各种天然和合成的Skp2抑制化合物。Skp2抑制剂或抑制化合物在细胞水平上对各种肿瘤的IC数据表明,在选择Skp2抑制化合物进行癌症治疗时,应考虑癌症类型、阶段和病理机制。